Objective: To investigate the effects and its potential mechanism of IKK2 inhibitor LY2409881 on proliferation, cell cycle and apoptosis of diffuse large B-cell lymphoma (DLBCL) cell lines.
Methods: CCK8 assay was used to detect the effect of LY2409881 on proliferation of DLBCL cell lines; Flow cytometry was used to analyze cell cycle; Western blot was used to analyze apoptosis and its potential mechanism.
Results: LY2409881 inhibited the proliferation of multiple DLBCL cell lines obviously, and caused G cell arrest. Furtherly, LY2409881 inhibited the expression of c-FLIP, induced the activation of DR4 and caspase 8. Meanwhile, LY2409881 induced the expression of pro-apoptotic protein BAX and inhibited the expression of anti-apoptotic protein MCL-1 and BCL-2.
Conclusion: LY2409881 inhibits the proliferation of DLBCL cell lines, causes G cell arrest and induces apoptosis via the endogenous and exogenous apoptotic pathways.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7534/j.issn.1009-2137.2018.04.024 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diffuse Large B-Cell Lymphoma/High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements: a study of 60 Cases.
Mod Pathol
January 2025
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address:
Classification of cases of diffuse large B-cell lymphoma (DLBCL)/high-grade B-cell lymphoma (HGBL) with MYC and BCL6 rearrangements, also known as BCL6 double hit lymphoma (DHL), is controversial. We assessed 60 cases of BCL6-DHL and compared this cohort to 224 cases of DHL with MYC and BCL2 rearrangements (BCL2-DHL) and 217 cases of DLBCL not otherwise specified. Compared with the DLBCL cohort, BCL6-DHL patients had more aggressive clinical features such as frequent extranodal involvement, high-stage disease, high IPI score and elevated serum lactate dehydrogenase level (p <0.
View Article and Find Full Text PDFEnhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.
Clin Cancer Res
January 2025
The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Purpose: More active high-dose chemotherapy (HDC) regimens are needed for autologous stem-cell transplantation (ASCT) for refractory lymphomas. Seeking HDC enhancement with a poly(ADP-ribose) polymerase (PARP) inhibitor, we observed marked synergy between olaparib and vorinostat/gemcitabine/busulfan/melphalan (GemBuMel) against lymphoma cell lines, mediated by inhibition of DNA damage repair. Our preclinical work led us to clinically study olaparib/vorinostat/GemBuMel with ASCT.
View Article and Find Full Text PDFThe predictive power of baseline metabolic and volumetric [F]FDG PET parameters with different thresholds for early therapy failure and mortality risk in DLBCL patients undergoing CAR-T-cell therapy.
Eur J Radiol Open
June 2025
Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Düsseldorf 40225, Germany.
Objective: [F]FDG imaging is an integral part of patient management in CAR-T-cell therapy for recurrent or therapy-refractory DLBCL. The calculation methods of predictive power of specific imaging parameters still remains elusive. With this retrospective study, we sought to evaluate the predictive power of the baseline metabolic parameters and tumor burden calculated with automated segmentation via different thresholding methods for early therapy failure and mortality risk in DLBCL patients.
View Article and Find Full Text PDFHypothermia, Hallucinations, and Atrial Fibrillation Secondary to Diffuse Large B-cell Lymphoma.
Cureus
December 2024
Emergency Medicine, Northwell Health, Manhasset, USA.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults, constituting a significant portion of global incidence rates. DLBCL can be further classified via genetic expression profiling into molecular subsets consisting of not-otherwise specified (NOS) subset being the most prevalent, germinal center B-cell-like (GCB) subset, and activated B-cell-like (ABC) subset. The ABC subset, marked by abnormal NF-κB signaling, is associated with poorer outcomes.
View Article and Find Full Text PDFHere, we have discussed the molecular mechanisms of p53-responsive microRNAs dysregulation in response to genotoxic stress in diffuse large B-cell lymphoma (DLBCL) patients. The role of micro ribonucleic acids (microRNAs) in p53-signaling cellular stress has been studied. MicroRNAs are the small non-coding RNAs, which regulate genes expression at post-transcriptional level.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!